A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B.
A. Philippe Chahinian, KATHLEEN JOY PROPERT, John Ware et al. · Journal of Clinical Oncology · 1989
The Cancer and Leukemia Group B (CALGB) conducted a prospective randomized trial to evaluate the role of warfarin and alternating chemotherapy in extensive small-cell lung cancer (SCCL). After stratification for sex and performance status, patients were randomly assigned to receive chemotherapy with methotrexate, doxorubicin (Adriamycin; Adria Laboratories, Columbus, OH), cyclophosphamide, and lomustine (CCNU) (MACC), or MACC plus warfarin (MACC + W), or mitomycin, etoposide, cisplatin, and hexamethylmelamine alternating with MACC (MEPH/MACC). Warfarin was given continuously to maintain a prothrombin time of one and one half to twice the control values. A total of 328 patients were enrolled, and 294 were evaluable. There was a statistically significant advantage in objective response rates (complete [CR] and partial responses [PR], respectively) for MACC + W (17% and 50%) as compared with MACC alone (8% and 43%) or MEPH/MACC (10% and 38%) (P = .012). Both failure-free survival (P = .054 Wilcoxon test) and overall survival (P = .098 Wilcoxon test) were higher on MACC + W (median, 6.6 months and 9.3 months, respectively), as compared with MACC (5.0 months and 7.9 months) and MEPH/MACC (5.0 months and 7.9 months). Toxicity was comparable among the three arms, except for increased hemorrhagic events on MACC + W, which were life-threatening in four patients (4%), and lethal in two others (2%). These data support the role of warfarin in the treatment of SCCL, but do not establish its mechanism of action. Warfarin deserves further studies in SCCL, particularly in patients with limited disease.
Cited by 193 works. doi:10.1200/jco.1989.7.8.993
Authors
- A. Philippe Chahinian
- KATHLEEN JOY PROPERT
- John Ware
- Bonnie Zimmer
- Michael C. Perry
- Vera Hirsh
- Arthur T. Skarin
- S. Kopel
- James F. Holland
- Robert L. Comis
References
- Regression Models and Life-Tables
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples
- Rationale for the use of alternating non-cross-resistant chemotherapy.
- The genetic origin of drug resistance in neoplasms: implications for systemic therapy.
- Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75
- Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75
- Superiority of Alternating Non-Cross-Resistant Chemotherapy in Extensive Small Cell Lung Cancer
- Prognostic factors in small cell carcinoma of the lung: a cancer and leukemia group B study.
- Implications of kinetic heterogeneity in clinical oncology.
- Rationale and experimental design for the va cooperative study of anticoagulation (warfarin) in the treatment of cancer